ElisaRSR™ Diabetes Autoantibody Assay
Type 1 Diabetes
CommercialActive
Key Facts
About DLD Diagnostika
DLD Diagnostika is a well-established, privately-held German diagnostics company with a 30+ year history. It has carved out a specialized niche in the IVD market by developing and commercializing high-sensitivity ELISA and RIA tests for challenging biomarkers in human and veterinary medicine. The company operates a revenue-generating, commercial-stage business model, serving both research and clinical laboratory markets globally with its portfolio of assays for complex conditions like pheochromocytoma, autoimmune neurological disorders, and kidney disease.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |